Radioembolization and targeted therapy for unresectable bile duct cancer
Treatments studied
Part of Cancer clinical trials.
This trial combines a liver-directed radiation therapy (radioembolization) with a targeted drug to treat a specific type of bile duct cancer that cannot be surgically removed. The goal is to see if this combination can shrink the tumor and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 80 years old.
- You weigh more than 66 pounds (30 kg).
- You have a type of bile duct cancer that starts in the liver (called intrahepatic cholangiocarcinoma) that cannot be removed with surgery.
- Your cancer has not been treated before with surgery or systemic therapy (drugs that go throughout the body).
- Your liver is working well (your doctor can confirm this).
- You do not have other active cancers or serious infections (like active hepatitis B or C, or tuberculosis), and you are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests whether combining chemotherapy (gemcitabine and cisplatin) and an immunotherapy drug (durvalumab) with targeted Y-90 radiation can shrink inoperable intrahepatic cholangiocarcinoma tumors. It’s looking for better tumor shrinking and improved cancer control.
This trial tests a combination of chemotherapy (gemcitabine and cisplatin) with the targeted therapy lenvatinib and the immunotherapy adebrelimab for people with advanced bile duct cancer that cannot be removed by surgery. It aims to see if this combination works better than standard treatments.
This study tests a combination of liver-directed therapy (D-TACE-HAIC), an immunotherapy drug (Envafolimab), and a targeted therapy pill (Lenvatinib) for people with a type of liver cancer (intrahepatic cholangiocarcinoma) that cannot be surgically removed. The goal is to see if this combination can shrink or control the cancer.
This trial tests a combination of chemotherapy directly into the liver artery, an immunotherapy drug, and a targeted therapy pill before surgery for a type of bile duct cancer that has a high chance of coming back. The goal is to see if this approach can improve outcomes for patients whose cancer is still removable but has certain high-risk features.
This trial tests a procedure called cryoablation, which freezes and destroys cancer cells, combined with a targeted therapy drug (anlotinib) for people with advanced bile duct cancer that has not responded to earlier treatments. The goal is to see if this combination can slow the cancer's growth and improve outcomes.
This trial studies whether combining Y-90 liver radiation with an immunotherapy drug (durvalumab) and chemo (gemcitabine and cisplatin) can better control locally advanced or metastatic intrahepatic cholangiocarcinoma (bile duct cancer in the liver). It may help shrink tumors and slow disease growth, depending on how well the treatment works for your cancer type and overall health.
Hear when a new Intrahepatic Cholangiocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.